NCM’s strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribution network in New York State. The American market for molecular imaging agents currently exceeds $1.3 billion annually and is expected to grow to over $3 billion by 2020.

Anwer Rizvi,
President & CEO, has a proven track record of developing a distribution network for PET in the United States, Europe and Asia. Due to his efforts at IBA, he in-licensed several compounds for IBA’s network, totaling a combined value of $500+ million. Mr. Rizvi was the founder and president of IBA Molecular from 2001-2009. Continue>>

Tour our up and coming state-of-the-art manufacturing facility

The radionuclides employed for imaging purposes are isotopes of radioactive elements such as uranium or iodine that produce gamma rays with high penetrating power that can be recorded by a gamma camera or scintillation detector that captures the images..>

View a quick presentation of the science behind radio-pharmaceuticals.
461 Park Avenue South
New York, NY 10016

Office:  212-719-2322
Fax: (212) 997-4119


© NCM USA LLC 2011 All Rights Reserved Home Contact us Investor Relations